Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive Lymphomas

Ipsita Pal, PhD, Sohani Das Sharma, PhD, Andre M. Grilo, PhD, Prabhjot S. Mundi, MD, Luigi Scotto, PhD, Abdullah Mahmood Ali, PhD, Luke E Berchowitz, PhD, Siddhartha Mukherjee, MD PhD, Owen O'Connor, MD PhD, Marko Jovanovic, PhD, Changchun Deng, MD PhD

Blood (2019) 134 (Supplement_1): 2864.

https://doi.org/10.1182/blood-2019-129528

Published: 2019

Journal Articles

CK2 Inhibitor CX4945 Shows Strong In Vivo Anti Leukemia Effect in AML Via Augmented Ikaros-Mediated Regulation of Global Epigenetic Landscape

Chandrika Gowda, MBBS, Chunhua Song, MD, Sadie Steffens, PhD, Yali Ding, PhD, Bo Zhang, Feng Yue, PhD, Soumya Iyer, PhD, Pavan kumar Dhanyamraju, PhD, Jonathon Payne, Morgann Reed, BS, Kimberly J. Payne, PhD, Sinisa Dovat, MD PhD

Blood (2019) 134 (Supplement_1): 2522.

https://doi.org/10.1182/blood-2019-131200

Published: 2019

Journal Articles

Identification of Thrombospondin-1 As a Novel Substrate of Cereblon Responsible for IMiDs-Induced Venous Thromboembolism

Kiwamu Hatakeyama, MD, Yoshikane Kikushige, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 631.

https://doi.org/10.1182/blood-2019-125670

Published: 2019

Journal Articles

Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

Chan Y. Cheah, Nicholas Wickham, MBBS, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Katharine L Lewis, FRCPath, MRCP, MBBS, Chi-Hung Hui, MBBS, Pek Sang Tang, MBBS, Tejasvi Turpuseema, Hari P Miskin, MSc, Jian-Ping Tang, PhD, Emmanuel Normant, PhD, Alejandro D. Ricart, MD, Constantine S. Tam, MBBS (Hons), MD

Blood (2019) 134 (Supplement_1): 4001.

https://doi.org/10.1182/blood-2019-126951

Published: 2019

Journal Articles

A CK1δ/CK1ε Regulated Metabolic Circuit Is a Therapeutic Vulnerability for Multiple Myeloma

Karen L Burger, PhD, Mark B. Meads, PhD, Anders Berglund, Paula S. Oliveira, Allison Distler, Praneeth Reddy Sudalagunta, PhD, Timothy Jacobson, Jamie Teer, PhD, Eric A. Welsh, PhD, Hongyue Dai, PhD, John M. Koomen, PhD, Alugubelli Raghunandan Reddy, Gabriel De Avila, Alexandre Tungesvik, MD, William Roush, PhD, Ariosto Siqueira Silva, PhD, Kenneth H. Shain, MD PhD, John Cleveland, PhD

Blood (2019) 134 (Supplement_1): 5537.

https://doi.org/10.1182/blood-2019-130830

Published: 2019

Journal Articles

Alterations in Secretome and Transcriptome of Bone Marrow Derived MSCs in Patients with Diffuse Large B-Cell Lymphoma without Bone Marrow Involvement

Nataliya A. Petinati, MD PhD, Natalia Sats, PhD, Nina J. Drize, PhD, Irina Malyants, Victoria Shender, PhD, Ksenia Anufrieva, PhD, Polina Shneider, Tatiana Grigorieva, PhD, Georgiy Arapidi, PhD, Maria Lagarkova, PhD, Ekaterina A. Fastova, MD, Aminat A. Magomedova, MD PhD, Sergey K. Kravchenko, MD PhD, Valeriy G. Savchenko, MD PhD

Blood (2019) 134 (Supplement_1): 1514.

https://doi.org/10.1182/blood-2019-122431

Published: 2019

Journal Articles

Bioavailable Dual-Protein Degraders of CK1α and Transcriptional Kinase CDK9 As Potential Therapeutics for Hematological Malignancies

Leah Fung, PhD, Aparajita Hoskote Chourasia, PhD, Eduardo Torres, MSc, Imelda Lam, BSc, Paul Erdman, MSc, David Hecht, PhD, Robert Sullivan, PhD, Brooke McElwee, BSc, Normand Richard, MSc, Avanthika Venkatachalam, MSc, Irit Snir-Alkalay, PhD, Kyle WH Chan, PhD, Frank Mercurio, PhD, Yinon Ben-Neriah, MD PhD, David I Stirling, PhD

Blood (2019) 134 (Supplement_1): 4643.

https://doi.org/10.1182/blood-2019-131834

Published: 2019

Journal Articles

Small Molecule Screens Identify CDK8-Inhibitors As Candidate Diamond-Blackfan Anemia Drugs

Blood (2018) 132 (Supplement 1): 753.

https://doi.org/10.1182/blood-2018-99-114570

Published: 2018

Journal Articles

Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation

Blood (2018) 132 (Supplement 1): 297.

https://doi.org/10.1182/blood-2018-99-117526

Published: 2018

Journal Articles

Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia

Blood (2018) 131 (11): 1206–1218.

https://doi.org/10.1182/blood-2017-05-786947

Published: 2018

Includes: Supplemental data

Journal Articles

CK2β regulates thrombopoiesis and Ca 2+ -triggered platelet activation in arterial thrombosis

Blood (2017) 130 (25): 2774–2785.

https://doi.org/10.1182/blood-2017-05-784413

Published: 2017

Includes: Multimedia, Supplemental data

Journal Articles

Transcriptional Regulation of the CDC42 Signaling Pathway By Ikaros in T-Cell Acute Lymphoblastic Leukemia

Sinisa Dovat, Zheng Ge, MD PhD, Kimberly Payne, Chandrika Gowda, MD, Chunhua Song, MD

Blood (2017) 130 (Supplement 1): 1213.

https://doi.org/10.1182/blood.V130.Suppl_1.1213.1213

Published: 2017

Journal Articles

A CK1δ/CK1ε-to-β-Catenin Circuit Is a Therapeutic Vulnerability for Primary and Drug Resistant Multiple Myeloma

Karen L Burger, PhD, Mark B. Meads, PhD, Ariosto Siqueira Silva, PhD, Paula Oliveira, Tuan Nguyen, Allison Distler, Maria Coelho Siqueira Silva, Timothy Jacobson, Jamie Teer, PhD, Hongyue Dai, PhD, William Roush, PhD, John Cleveland, PhD, Kenneth H Shain, MD PhD

Blood (2017) 130 (Supplement 1): 591.

https://doi.org/10.1182/blood.V130.Suppl_1.591.591

Published: 2017

Journal Articles

Hematopoietic-Specific CSNK2B Loss in Mice Causes Impaired Erythropoiesis

Laura Quotti Tubi, PhD, Sara Canovas Nunes, PhD, Marilena Carrino, PhD, Ketty Gianesin, PhD, Sabrina Manni, PhD, Odile Filhol-Cochet, PhD, Brigitte Boldyreff, PhD, Livio Trentin, MD, Gianpietro Semenzato, MD, Francesco Piazza, MD

Blood (2017) 130 (Supplement 1): 82.

https://doi.org/10.1182/blood.V130.Suppl_1.82.82

Published: 2017

Journal Articles

Casein Kinase II Inhibition By CX-4945 and Epigenetic Modulation By Decitabine Demonstrate Significant Antiproliferative Activity As Single Agents As Well As in Combination in Acute B-Lymphoblastic Leukemia Cells

Anna Richter, Catrin Roolf, PhD, Sina Sender, M.Sc., Weibo Kong, M.Sc., Gudrun Knübel, Anett Sekora, Yvonne Saara Gladbach, M.Sc., Mohamed Hamed, PhD, Georg Fuellen, PhD, Brigitte Vollmar, MD, Irmela Jeremias, Jens P. Panse, MD, Hugo Murua Escobar, PhD, Christian Junghanss, MD

Blood (2017) 130 (Supplement 1): 3887.

https://doi.org/10.1182/blood.V130.Suppl_1.3887.3887

Published: 2017

Journal Articles

Epigenetic Regulation of c-Kit Expression in Acute Myeloid Leukemia By Oncogenic Casein Kinase II (CK2)

Chandrika Gowda, MD, Mexian Xiang, PhD, Chunhua Song, MD, Kimberly Payne, Sinisa Dovat

Blood (2017) 130 (Supplement 1): 3787.

https://doi.org/10.1182/blood.V130.Suppl_1.3787.3787

Published: 2017

Journal Articles

Protein Kinase CSNK1A Regulates the Multiple Myeloma Plasma Cell-Microenvironment Interplay

Sabrina Manni, PhD, Ketty Gianesin, PhD, Marilena Carrino, PhD, Federica Costa, PhD, Gregorio Barilà, MD, Renato Zambello, MD, Nicola Giuliani, MD PhD, Livio Trentin, MD, Gianpietro Semenzato, MD, Francesco Piazza, MD

Blood (2017) 130 (Supplement 1): 4398.

https://doi.org/10.1182/blood.V130.Suppl_1.4398.4398

Published: 2017

Journal Articles

An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

Blood (2017) 130 (Supplement 1): 4037.

https://doi.org/10.1182/blood.V130.Suppl_1.4037.4037

Published: 2017

Journal Articles

Umbralisib/TGR-1202 As a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas

Ipsita Pal, PhD, Yu Ri Kim, MD, Luigi Scotto, PhD, Mark R Lipstein, PhD, Abdullah Mahmood Ali, PhD, Siddhartha Mukherjee, MD PhD, Susan E. Bates, MDPhD, Owen A. O'Connor, MD, PhD, Changchun Deng, MD PhD

Blood (2017) 130 (Supplement 1): 2809.

https://doi.org/10.1182/blood.V130.Suppl_1.2809.2809

Published: 2017

Journal Articles

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies

Changchun Deng, MD PhD, Mark Lipstein, Luigi Scotto, PhD, Xavier O Jirau Serrano, B.S., Michael Mangone, PhD, Shirong Li, PhD, Jeremie Vendome, PhD, Yun Hao, Xiaoming Xu, Xiaoping Liu, MD PhD, Ipsita Pal, PhD, Shi-Xian Deng, PhD, Nicholas P. Tatonetti, PhD, Suzanne Lentzsch, MD PhD, Barry Honig, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD

Blood (2016) 128 (22): 291.

https://doi.org/10.1182/blood.V128.22.291.291

Published: 2016

NARROW

Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive Lymphomas

CK2 Inhibitor CX4945 Shows Strong In Vivo Anti Leukemia Effect in AML Via Augmented Ikaros-Mediated Regulation of Global Epigenetic Landscape

Identification of Thrombospondin-1 As a Novel Substrate of Cereblon Responsible for IMiDs-Induced Venous Thromboembolism

Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

A CK1δ/CK1ε Regulated Metabolic Circuit Is a Therapeutic Vulnerability for Multiple Myeloma

Alterations in Secretome and Transcriptome of Bone Marrow Derived MSCs in Patients with Diffuse Large B-Cell Lymphoma without Bone Marrow Involvement

Bioavailable Dual-Protein Degraders of CK1α and Transcriptional Kinase CDK9 As Potential Therapeutics for Hematological Malignancies

Small Molecule Screens Identify CDK8-Inhibitors As Candidate Diamond-Blackfan Anemia Drugs

Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation

Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia

CK2β regulates thrombopoiesis and Ca 2+ -triggered platelet activation in arterial thrombosis

Transcriptional Regulation of the CDC42 Signaling Pathway By Ikaros in T-Cell Acute Lymphoblastic Leukemia

A CK1δ/CK1ε-to-β-Catenin Circuit Is a Therapeutic Vulnerability for Primary and Drug Resistant Multiple Myeloma

Hematopoietic-Specific CSNK2B Loss in Mice Causes Impaired Erythropoiesis

Casein Kinase II Inhibition By CX-4945 and Epigenetic Modulation By Decitabine Demonstrate Significant Antiproliferative Activity As Single Agents As Well As in Combination in Acute B-Lymphoblastic Leukemia Cells

Epigenetic Regulation of c-Kit Expression in Acute Myeloid Leukemia By Oncogenic Casein Kinase II (CK2)

Protein Kinase CSNK1A Regulates the Multiple Myeloma Plasma Cell-Microenvironment Interplay

An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

Umbralisib/TGR-1202 As a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only